A randomized, open, parallel design of polyethylene glycol (peg) recombinant human granulocyte stimulating factor injection 6 mg / 0.6 1.0 mg/mL and 3 mL in healthy male volunteers in pharmacokinetics and pharmacodynamics study

Trial Profile

A randomized, open, parallel design of polyethylene glycol (peg) recombinant human granulocyte stimulating factor injection 6 mg / 0.6 1.0 mg/mL and 3 mL in healthy male volunteers in pharmacokinetics and pharmacodynamics study

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Neutropenia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 08 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top